Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The Polycystic Ovarian Syndrome (PCOS) is a common disorder related to ovulation problems.
Clomiphene citrate (CC) is the drug of first choice for this condition. Nevertheless, CC has
a detrimental effect over uterine receptivity.
Raloxifene is a Selective Estrogen Receptor Modulator, that does not have a detrimental
effect over the endometrium, and also increase the serum levels of FSH, thus, inducting
ovulation.
The objective of this study is to compare the ovulation rate in PCOS patients between
clomiphene citrate and raloxifene in a double blind randomized trial.